Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Deferasirox-calcium-vitamin D3 Therapy for Postmenopausal Osteoporosis (PMOP) (PMOP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02854722
Recruitment Status : Recruiting
First Posted : August 3, 2016
Last Update Posted : May 17, 2018
Sponsor:
Information provided by (Responsible Party):
You-Jia Xu, Second Affiliated Hospital of Soochow University

Brief Summary:

In 2006, Weinberg proposed a hypothesis that iron accumulation was a risk factor for osteoporosis. Osteoporosis is a common complication in various diseases, such as hemochromatosis, African hemosiderosis, thalassemia, and sickle cell disease, which all share iron accumulation as a common denominator. Moreover, a 3-year retrospective longitudinal study has shown that iron accumulation was also associated with osteoporosis in healthy adults and especially that it can increase the risk of fractures in postmenopausal women. Based on these observations, iron chelation therapy may have a promising future in the treatment of iron accumulation-related osteoporosis by removing iron from the body.

The purpose of this study is to determine whether the addition of the iron chelator, deferasirox, to standard therapy for postmenopausal osteoporosis, is safe and effective.


Condition or disease Intervention/treatment Phase
Postmenopausal Osteoporosis Drug: Deferasirox and calcium-vitamin D3 Drug: Calcium-vitamin D3 Phase 2

Detailed Description:

Postmenopausal osteoporosis (PMOP) is a systemic bone metabolism disease, characterized by progressive bone loss following menopause and a subsequent increase in fracture risk. Estrogen deficiency as a result of menopause is known to increase bone resorption and accelerate bone loss. Furthermore, postmenopausal women may exhibit iron accumulation, in addition to estrogen deficiency. Elevated iron levels are a risk factor for PMOP in postmenopausal women, and reducing the iron overload by iron chelators has been demonstrated to benefit bone cell metabolism in vitro and improve the bone in vivo by normalizing osteoclastic bone resorption and formation.

Although the safety and efficacy of deferasirox have been evaluated in iron-overloaded patients extensively, there are no data in iron-accumulated postmenopausal women, let alone in iron-accumulated postmenopausal women with osteoporosis. Therefore, at the currently planned dose, confirming safety and efficacy is essential in the current study to lay the groundwork for a future phase III clinical trial.

This is a prospective, phase II, randomized, open label, placebo-controlled study of calcium-vitamin D3 plus deferasirox vs. calcium-vitamin D3 for postmenopausal osteoporosis. Ten postmenopausal women diagnosed with osteoporosis by DXA, who were accompanied by iron accumulation (serum 500ng/ml≤ferritin≤1000ng/ml), will be randomized to receive calcium-vitamin D3 plus deferasirox or calcium-vitamin D3 (n = 5 per arm).

The primary objective is to determine the safety and tolerability of adjunctive deferasirox therapy in postmenopausal women being treated with calcium-vitamin D3 for osteoporosis, and to obtain exploratory data on the efficacy of the iron chelation treatment. The reduction in iron levels with deferasirox may provide a viable therapeutic option for mitigating the iron accumulation associated with PMOP.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Study of Deferasirox-calcium-vitamin D3 to Treat Postmenopausal Osteoporosis (PMOP)
Actual Study Start Date : January 15, 2018
Estimated Primary Completion Date : June 15, 2019
Estimated Study Completion Date : June 15, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Deferasirox and calcium-vitamin D3

Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.

Calcium 500 mg and Vitamin D3 800 IU should also be taken daily as a basic therapy.

Drug: Deferasirox and calcium-vitamin D3

deferasirox and calcium-vitamin D3 Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.

Calcium 500 mg and vitamin D3 800 IU should also be taken daily as a basic therapy.


Drug: Calcium-vitamin D3
Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.

Placebo Comparator: Calcium-vitamin D3
Calcium 500 mg and Vitamin D3 800 IU are taken daily as a basic therapy.
Drug: Calcium-vitamin D3
Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.




Primary Outcome Measures :
  1. Number of participants with adverse events [ Time Frame: 12 months ]

    An adverse event was any untoward medical occurrence in participants, and did not necessarily need to have a causal relationship with the drug in the trial. The relationship of each adverse event to study drug or the severity of each adverse event was judged by the investigator, as described below. A serious adverse event is an adverse event occurring at any dose that resulted in any of the following outcomes or actions:

    fatal or life-threatening; requires inpatient hospitalization; persistent or significant disability/incapacity;


  2. Number of participants with abnormal blood pressure, heart rate, body temperature, and/or physical examination that are related to the treatment [ Time Frame: 12 months ]
  3. Bone mineral density [ Time Frame: Baseline, Month 6, Month 12 ]
    Bone mineral density was measured by dual energy X-ray absorptiometry (DXA) scan. Percent changes in DXA Bone Mineral Density from baseline to month 6 and month 12 of the trial in all patients. Percent change from Baseline was calculated as (BMD at Month 6 or Month 12 - BMD at Baseline)/BMD at Baseline * 100%.


Secondary Outcome Measures :
  1. Change from baseline in serum C-terminal telopeptide of type I collagen (β-CTX) [ Time Frame: Baseline, Month 3, Month 6, Month 9 and Month 12 ]
  2. Change from baseline in serum N-aminoterminal prepeptide of type I procollagen (P1NP) [ Time Frame: Baseline, Month 3, Month 6, Month 9 and Month 12 ]
  3. Change from baseline in serum ferritin [ Time Frame: Baseline, Month 3, Month 6, Month 9 and Month 12 ]
  4. Change from baseline in blood chemistry [ Time Frame: Baseline, Week 2, Week 4 and Month 3, Month 6, Month 9, Month 12 of the trial ]
  5. Change from baseline in hematology [ Time Frame: Baseline, Week 2, Week 4 and Month 3, Month 6, Month 9, Month 12 of the trial ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Lumbar spine or hip BMD T-score ≤-2.5 SD.
  2. Elevated serum ferritin (females: serum 500ng/ml≤ferritin≤1000ng/ml).

Exclusion Criteria:

  1. Anemia < 10 g/dl
  2. Serum liver enzymes or bilirubin above the upper limit of normal at screening.
  3. Patients with creatinine clearance <60 ml/min will be excluded.
  4. Known allergy or contraindication to the administration of Deferasirox.
  5. History of blood transfusion during the 6 months prior to study entry.
  6. Oral iron supplementation within the last 4 weeks of study entry.
  7. Treatment with phlebotomy within 2 weeks of screening visit.
  8. Patient is already taking deferasirox therapy for any reason at the time of screening.
  9. Patients currently or previously treated with deferiprone or Deferasirox.
  10. Patients with active inflammatory diseases that may interfere with the accurate measurement of serum ferritin.
  11. Patients with a diagnosis of a clinically relevant cataract or a previous history of clinically relevant ocular toxicity related to iron chelation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02854722


Contacts
Layout table for location contacts
Contact: You-Jia Xu, Ph.D,M.D. +86 512 67783746 xuyoujia@medmail.com.cn

Locations
Layout table for location information
China, Jiangsu
Second Affiliated Hospital of Soochow University Recruiting
Suzhou, Jiangsu, China, 215004
Contact: Youjia Xu, Ph.D,M.D.    +86 512 67783346    xuyoujia@medmail.com.cn   
Principal Investigator: You-Jia Xu, Ph.D,M.D.         
Sub-Investigator: Bin Chen, M.D.         
Sub-Investigator: Guang-fei Li, M.D.         
Sub-Investigator: Guang-si Shen, Ph.D         
Sponsors and Collaborators
Second Affiliated Hospital of Soochow University
Investigators
Layout table for investigator information
Principal Investigator: You-Jia Xu, Ph.D,M.D. Second Afflilated Hospital of Soochow University

Publications:

Layout table for additonal information
Responsible Party: You-Jia Xu, Director of Science and Education Department, Second Affiliated Hospital of Soochow University
ClinicalTrials.gov Identifier: NCT02854722     History of Changes
Other Study ID Numbers: BL2014044
First Posted: August 3, 2016    Key Record Dates
Last Update Posted: May 17, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by You-Jia Xu, Second Affiliated Hospital of Soochow University:
deferasirox
iron accumulation
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoporosis
Osteoporosis, Postmenopausal
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Vitamin D
Ergocalciferols
Calcium, Dietary
Cholecalciferol
Vitamins
Calcium
Deferasirox
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents
Iron Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action